Roivant Sciences, a three-year-old, New York-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1.1 billion in equity led by the Softbank Vision Fund — making it the latest in a string of enormous bets by Softbank, and putting the young outfit more squarely on the radar of the tech world. Roivant focuses on… Read More

from iFeeltech IT News Mix4 https://techcrunch.com/2017/08/09/roivant-which-creates-companies-around-orphaned-drugs-just-raised-1-1-billion-from-softbank/?ncid=rss

Advertisements